Translate
About
Pharmaessentia (TW:6446) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 2 2026
PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
Feb 9 2026
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
Jan 27 2026
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
Jan 13 2026
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Jan 12 2026
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Financials
Revenue
NT$15.63 B
Market Cap
NT$234.57 B
P/E Ratio
46.50
EPS
13.59
Dividend Yield
0.17%